What Tissue Regenix Group does

Tissue Regenix Group is a UK-headquartered regenerative medicine company that develops, manufactures, and distributes biological tissue products for surgical applications. The company operates two complementary platform technologies: dCELL®, a decellularization process that removes cellular material from animal (porcine) and human tissue to create biocompatible scaffolds, and BioRinse™, a complementary platform for processing bone and soft tissue allografts and xenografts. Its commercial portfolio includes OrthoPure XT, a porcine-derived decellularized ligament reconstruction implant for ACL procedures (CE and UKCA certified), and AmnioWorks™, an air-dried acellular amniotic membrane for wound and surgical applications with a 5-year shelf life.

The company operates from two facilities: a Leeds headquarters responsible for porcine tissue medical device manufacturing and acting as an R&D hub linked to the University of Leeds, and a San Antonio, Texas facility (formerly CellRight Technologies, acquired in 2017) that processes, stores, and distributes Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/P) to the US market. Products are sold directly to hospitals, surgeons, and medical professionals, supplemented by approved distribution partners across the US, UK, and Europe. The company holds ISO 13485:2016 certification at both facilities, FDA registration, AATB accreditation, CE/UKCA marks for OrthoPure XT, and multiple US state tissue bank licenses plus Canadian licensure.

Revenue is generated through one-time product sales of regenerative allografts, xenografts, HCT/P products, and medical devices across clinical specialties including orthopaedics/sports medicine, spine, wound care, and extremities. Pricing is not publicly disclosed. The company was previously publicly traded on AIM under ticker TRX but was suspended from trading in October 2025 and announced plans in December 2025 to raise £17.5 million via a secured Convertible Loan Note, cancel AIM trading, delist, and re-register as a private limited company. The financial restructuring is occurring alongside restatements of FY24 and H125 results and multiple board changes, indicating the company is in a transitional corporate phase.

Name

Tissue Regenix Group

Legal name

Tissue Regenix Ltd.

Website

https://tissueregenixus.com

Company type

Private

Founded year

2008

Operating status

Operating

Short description

Tissue Regenix Group is a UK-headquartered regenerative medicine company that develops and manufactures allografts and xenografts (including the OrthoPure XT ligament implant and AmnioWorks amniotic membrane) for hospitals and surgeons across orthopaedics, spine, wound care, and extremities, using proprietary dCELL® and BioRinse™ decellularization platform technologies.

Ownership category

akta.pro rank

Product category

Regenerative Medical Devices and Tissue Allografts

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Sports Medicine & Soft Tissue Repair Implants (Anchors/Grafts/Meniscal Repair) (HLAHAEAF)

akta.pro secondary industries

Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG), Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG), Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH), Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE)

Keywords

• Regenerative medicine
• Decellularised tissue scaffolds
• Allograft processing
• Xenograft implants
• Orthopaedic biologics

Headquarters

HQ city

Leeds

HQ country

United Kingdom

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device and Tissue Products: Sale of regenerative tissue products including allografts, xenografts, HCT/P products, and medical devices such as OrthoPure® XT Ligament Reconstruction Implant and AmnioWorks™ birth tissue products

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

Tissue Regenix Group develops and manufactures regenerative medical devices, allografts, and xenografts for surgical applications using proprietary dCELL® decellularisation and BioRinse™ tissue processing platforms. Named products include OrthoPure® XT Ligament Reconstruction Implant (decellularised porcine tendon for ACL reconstruction) and AmnioWorks™ acellular amniotic membrane patches for wound care and surgical protection. Products are sold to hospitals, surgeons, and approved distribution partners across orthopaedics, spine, sports medicine, wound care, and extremity reconstruction.

Product overview

Tissue Regenix Group is a regenerative medicine company offering a portfolio of biological tissue products built on two complementary platform technologies: dCELL® and BioRinse™. The product portfolio includes AmnioWorks™ (an acellular amniotic membrane for birth tissue applications), OrthoPure® XT Ligament Reconstruction Implant (a porcine-derived decellularised tendon scaffold for ACL reconstruction), and allograft/xenograft processing products. The platforms serve clinical areas including orthopaedics, spine, sports medicine, wound care, and extremities.

Differentiator

Problem solved

Functional benefit

Brands

• AmnioWorks™: Birth tissue product line derived from human amniotic membrane, serving as an acellular amniotic membrane patch for surgical and trauma applications.
• OrthoPure® XT

Products and services

• OrthoPure® XT Ligament Reconstruction Implant A biological ligament reconstruction implant made from porcine tendon tissue decellularised using dCELL® Technology. Provides a biocompatible tissue scaffold for cellular repopulation and eventual regeneration. Used for ACL reconstruction procedures by orthopaedic surgeons. CE mark approved in Europe and UKCA certified.
• AmnioWorks™

Quantifiable outcome

• Eliminates the need for 'donor site' surgery, reducing pain and potentially leading to faster recovery times (OrthoPure® XT)

Segments5 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• University of LeedscoreStrategic or Co-development PartnerStrong research and development connections with the University of Leeds. The Leeds facility serves as an R&D hub for potential future portfolio developments alongside its manufacturing operations. This partnership supports innovation in regenerative medicine and provides access to academic research capabilities.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• MiMedx Group: Regenerative medicine company commercializing human placental tissue allografts (e.g., EpiFix, AmnioFix) across wound care, surgical, and sports-medicine indications. Directly comparable to Tissue Regenix on product format (acellular tissue grafts), regulatory pathway (HCT/P), and multi-segment GTM across wound care, orthopaedics, and surgical recovery.
• MTF Biologics: Non-profit tissue bank and one of the largest processors of allografts (musculoskeletal, wound, sports medicine) globally. Direct competitor in the HCT/P allograft distribution channel serving hospitals and orthopaedic surgeons, with overlapping portfolio breadth across bone, soft tissue, and birth tissue.
• LifeNet Health: Non-profit tissue banking organization distributing allografts and xenograft-derived products for orthopaedics, sports medicine, and wound care. Comparable on the HCT/P processing/distribution model (AATB-accredited, multi-state licensed) and on multi-segment sports-medicine/wound-care GTM.
• AlloSource: Non-profit tissue bank producing allografts for orthopaedic, spine, sports-medicine, and wound-care applications. Direct match on the HCT/P distribution model and on the multi-vertical regenerative-tissue commercial approach that Tissue Regenix pursues.
• Organogenesis Holdings: Public regenerative-medicine company focused on wound-care and surgical biologics, including Apligraf and amniotic membrane products (Affinity, NuShield). Direct match on the regenerative wound-care / birth-tissue product overlap with AmnioWorks™ and on hospital-channel sales motion.

Broad incumbents

• Arthrex: Privately held global leader in orthopaedic sports medicine and soft-tissue repair, with an extensive graft portfolio (allografts, autograft-harvesting systems, synthetic options) plus fixation devices. Direct competitor for ACL reconstruction surgeons, but operates as a broad incumbent across the entire sports-medicine toolkit versus Tissue Regenix's graft-focused niche.
• Smith+Nephew: Global medical-device incumbent with a significant sports-medicine and orthobiologics franchise (including REGENETEN, INTRAFIX, and graft alternatives). Direct overlap in ACL reconstruction and soft-tissue repair but operates at a vastly larger scale across multiple device categories.
• Integra LifeSciences: Diversified medical-device company with regenerative-tissue and wound-care portfolios (e.g., Integra dermal regeneration template, amniotic membrane products). Comparable on regenerative wound/skin substitutes and on the multi-vertical medical device GTM, though broader portfolio.
• Stryker: Diversified orthopaedic and surgical-device giant with sports-medicine and orthobiologics offerings (formerly Wright Medical). Indirect competitor in ACL reconstruction graft procurement and a broader incumbent in the orthopaedic sports-medicine market that hospitals routinely consider.

Others

• Coloplast: Wound-care and ostomy specialist with significant footprint in advanced wound dressings and surgical-site management. Adjacent comparator on the wound-care commercial channel rather than a direct graft competitor — relevant when sizing AmnioWorks™ sales opportunity.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tissue Regenix Group